Last updated 9 days ago
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
528 patients around the world
Available in Argentina, United States
Amgen
20Research sites
528Patients around the world
This study is for people with
Esophageal cancer
Gastric cancer
Gastroesophageal cancer
Requirements for the patient
To 100 Years
All Gender
Medical requirements
Sites
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro
Recruiting
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Recruiting
Fundación Cori para la Investigación y Prevención del Cáncer - La Rioja
Recruiting
Hospital Provincial del Centenario - Rosario, Santa Fe
Recruiting
Exelsus - Oncología Clínica - Tucumán
Recruiting
Fundación Ars Médica - San Salvador de Jujuy
Recruiting
Centro Médico Austral OMI - CABA
Recruiting
Sanatorio Allende (Nueva Córdoba)
Recruiting
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Fundación Respirar
Recruiting
StudyFORTITUDE-102
SponsorAmgen
Study typeInterventional
Conditions
Esophageal cancerGastric cancerGastroesophageal cancer
Requirements
To 100 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05111626
